Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Obesity | Research

Anti-obesity effect of Neoagaro-oligosaccharides with overweight and obese subjects: a 16-week, randomized, double-blind, placebo-controlled clinical trial

Authors: Hyang-Im Baek, Ki-Chan Ha, Yu Kyung Park, Je Hyeon Lee, Eun Joo Kim, Hye-Jeong Ko, Jong Cheon Joo

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Background

This trial aimed to evaluate the anti-obesity effects and safety of Neoagaro-oligosaccharides (NAOs) in humans in a 16 week, randomized, double-blind, placebo-controlled clinical trial.

Methods

One hundred overweight or obese subjects with a body mass index of 23 to 34.9 kg/m2 and a percent body fat of > 25% for males or > 30% for females were enrolled. NAOs or placebo products were administered at 3 g (twice a day, four capsules once) each for 16 weeks. Efficacy and safety biomarkers were measured before and after intervention.

Results

After 16 weeks of intervention, the group administered with NAOs had statistically significant decreases in visceral fat area and visceral-subcutaneous fat area ratio compared to the placebo group. The NAOs group suppressed the increase in weight and BMI compared to the placebo group, which was significant between groups. High-density lipoprotein- cholesterol was increased in the group administered with NAOs, which showed a significant trend compared to the placebo group. Clinical changes were not observed for any safety biomarkers.

Conclusions

These results suggest that NAOs have a beneficial effect on obesity. Thus, NAOs could be used as an anti-obesity supplement without side effects.

Trial registration

cris.nih.go.kr: (KCT0006640, 07/10/2021).
Literature
1.
Roslim NA, Ahmad A, Mansor M, Aung MMT, Hamzah F, Hassan H, Lua PL. Hypnotherapy for overweight and obese patients: a narrative review. J Integr Med. 2021;19(1):1–5.CrossRefPubMed
2.
3.
Cho YG, Yang YJ, Yoon YS, Lee ES, Lee JH, Jeong Y, Kang CH. Effect of MED-02 containing two probiotic strains, limosilactobacillus fermentum MG4231 and MG4244, on body Fat reduction in overweight or obese subjects: a Randomized, Multicenter, Double-Blind, placebo-controlled study. Nutrients 2022, 14(17).
4.
5.
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty Liver Disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82–97.CrossRefPubMed
6.
7.
Purton T, Mond J, Cicero D, Wagner A, Stefano E, Rand-Giovannetti D, Latner J. Body dissatisfaction, internalized weight bias and quality of life in young men and women. Qual Life Res. 2019;28(7):1825–33.CrossRefPubMed
8.
Busutil R, Espallardo O, Torres A, Martinez-Galdeano L, Zozaya N, Hidalgo-Vega A. The impact of obesity on health-related quality of life in Spain. Health Qual Life Outcomes. 2017;15(1):197.CrossRefPubMedPubMedCentral
9.
Yeh TL, Chen HH, Chiu HH, Chiu YH, Hwang LC, Wu SL. Morbidity associated with overweight and obesity in health personnel: a 10-year retrospective of hospital-based cohort study in Taiwan. Diabetes Metab Syndr Obes. 2019;12:267–74.CrossRefPubMedPubMedCentral
10.
Peng FLHH, Nor NM, Said R. Burden of Disease attributable to overweight and obesity in Malaysia. Malays J Public Health Med. 2018;18(1):11–8.
11.
Choi HI, Cha JM, Jeong IK, Cho IJ, Yoon JY, Kwak MS, Jeon JW, Kim SJ. Efficacy and safety of Gelidium Elegans intake on bowel symptoms in obese adults: a 12-week randomized double-blind placebo-controlled trial. Med (Baltim). 2019;98(17):e14981.CrossRef
12.
Xu SY, Kan J, Hu Z, Liu Y, Du H, Pang GC, Cheong KL. Quantification of Neoagaro-Oligosaccharide production through enzymatic hydrolysis and its anti-oxidant activities. Molecules 2018, 23(6).
13.
Hong SJ, Lee JH, Kim EJ, Yang HJ, Park JS, Hong SK. Anti-obesity and anti-diabetic effect of Neoagarooligosaccharides on High-Fat Diet-Induced obesity in mice. Mar Drugs 2017, 15(4).
14.
Lin F, Yang D, Huang Y, Zhao Y, Ye J, Xiao M. The potential of Neoagaro-oligosaccharides as a treatment of type II Diabetes in mice. Mar Drugs 2019, 17(10).
15.
Oh JK, Vasquez R, Kim SH, Lee JH, Kim EJ, Hong S-K, Kang D-K. Neoagarooligosaccharides modulate gut microbiota and alleviate body weight gain and metabolic syndrome in high-fat diet-induced obese rats. J Funct Foods. 2022;88:104869.CrossRef
16.
Choi J, Kim KJ, Koh EJ, Lee BY. Gelidium Elegans regulates the AMPK-PRDM16-UCP-1 pathway and has a synergistic effect with Orlistat on Obesity-Associated Features in mice Fed a High-Fat Diet. Nutrients 2017, 9(4).
17.
Yang JH, Cho SS, Kim KM, Kim JY, Kim EJ, Park EY, Lee JH, Ki SH. Neoagarooligosaccharides enhance the level and efficiency of LDL receptor and improve cholesterol homeostasis. J Funct Foods. 2017;38:529–39.CrossRef
18.
Shao-Chi Wu T-NW. Algal-oligosaccharide-lysates prepared by two bacterial agarases stepwise hydrolyzed and their anti-oxidative properties. Fish Sci. 2005;71:1149–59.CrossRef
19.
Chen HM, Yan XJ. Antioxidant activities of agaro-oligosaccharides with different degrees of polymerization in cell-based system. Biochim Biophys Acta. 2005;1722(1):103–11.CrossRefPubMed
20.
21.
Kang OL, Ghani M, Hassan O, Rahmati S, Ramli N. Novel agaro-oligosaccharide production through enzymatic hydrolysis: physicochemical properties and antioxidant activities. Food Hydrocolloids. 2014;42(2):304–8.CrossRef
22.
Enoki T, Tominaga T, Takashima F, Ohnogi H, Sagawa H, Kato I. Anti-tumor-promoting activities of agaro-oligosaccharides on two-stage mouse skin carcinogenesis. Biol Pharm Bull. 2012;35(7):1145–9.CrossRefPubMed
23.
Enoki T, Tanabe M, Shimomura M, Ohnogi H. Induction mechanism of heme oxygenase-1 and anti-inflammatory activity by agaro-oligosaccharides. Nippon Shokuhin Kogyo Gakkaishi. 2010;57:157–62.CrossRef
24.
Higashimura Y, Naito Y, Takagi T, Tanimura Y, Mizushima K, Harusato A, Fukui A, Yoriki H, Handa O, Ohnogi H, et al. Preventive effect of agaro-oligosaccharides on non-steroidal anti-inflammatory drug-induced small intestinal injury in mice. J Gastroenterol Hepatol. 2014;29(2):310–7.CrossRefPubMed
25.
Kim JH, Yun EJ, Yu S, Kim KH, Kang NJ. Different levels of skin whitening activity among 3,6-Anhydro-l-Galactose, agarooligosaccharides, and Neoagarooligosaccharides. Mar Drugs. 2017;15(10):321.CrossRefPubMedPubMedCentral
26.
Kobayashi R, Takisada M, Suzuki T, Kirimuraab K, Usamiab S. Neoagarobiose as a novel moisturizer with whitening effect. Biosci Biotechnol Biochem. 1997;61:162–3.CrossRefPubMed
27.
Organization WH. Global physical activity questionnaire (GPAQ) analysis guide. In.
28.
Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr. 2000;130(12):2943–8.CrossRefPubMed
29.
Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404.CrossRefPubMed
30.
Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance–a mini-review. Gerontology. 2009;55(4):379–86.CrossRefPubMed
31.
Choi B, Steiss D, Garcia-Rivas J, Kojaku S, Schnall P, Dobson M, Baker D. Comparison of body mass index with waist circumference and skinfold-based percent body fat in firefighters: adiposity classification and associations with Cardiovascular Disease risk factors. Int Arch Occup Environ Health. 2016;89(3):435–48.CrossRefPubMed
32.
Ortega FB, Lavie CJ, Blair SN. Obesity and Cardiovascular Disease. Circ Res. 2016;118(11):1752–70.CrossRefPubMed
33.
Kawada T, Andou T, Fukumitsu M. Waist circumference, visceral abdominal fat thickness and three components of metabolic syndrome. Diabetes Metab Syndr. 2016;10(1):4–6.CrossRefPubMed
34.
Roriz AK, Passos LC, de Oliveira CC, Eickemberg M, Moreira Pde A, Sampaio LR. Evaluation of the accuracy of anthropometric clinical indicators of visceral fat in adults and elderly. PLoS ONE. 2014;9(7):e103499.CrossRefPubMedPubMedCentral
35.
Nagaretani H, Nakamura T, Funahashi T, Kotani K, Miyanaga M, Tokunaga K, Takahashi M, Nishizawa H, Kishida K, Kuriyama H. Visceral fat is a major contributor for multiple risk factor clustering in Japanese men with impaired glucose tolerance. Diabetes Care. 2001;24(12):2127–33.CrossRefPubMed
36.
Kaess BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, Fox CS. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012;55(10):2622–30.CrossRefPubMedPubMedCentral
37.
Heart N, Lung, Institute B, Diabetes NIo, Diseases K. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Heart, Lung, and Blood Institute; 1998.
38.
WHO. : Obesity: preventing and managing the global epidemic. Report of a WHO consultation. 2000.
39.
WHO. : The Asia-Pacific perspective: redefining obesity and its treatment. 2000.
40.
Lampure A, Castetbon K, Hanafi M, Deglaire A, Schlich P, Peneau S, Hercberg S, Mejean C. Relative influence of socioeconomic, psychological and sensory characteristics, physical activity and Diet on 5-Year Weight Gain in French adults. Nutrients 2017, 9(11).
41.
Wharton S, Astrup A, Endahl L, Lean MEJ, Satylganova A, Skovgaard D, Wadden TA, Wilding JPH. Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. Int J Obes (Lond). 2021;45(5):923–33.CrossRefPubMedPubMedCentral
42.
Elisabeth AL, Karlen SB, Magkos F. The Effect of COVID-19-related lockdowns on Diet and physical activity in older adults: a systematic review. Aging Dis. 2021;12(8):1935–47.CrossRefPubMed
43.
Bishop FL, Adams AE, Kaptchuk TJ, Lewith GT. Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebos. PLoS ONE. 2012;7(6):e39661.CrossRefPubMedPubMedCentral
44.
Wu Y, Pan X, Zhang S, Wang W, Cai M, Li Y, Yang F, Guo H. Protective effect of corn peptides against alcoholic liver injury in men with chronic alcohol consumption: a randomized double-blind placebo-controlled study. Lipids Health Dis. 2014;13:192.CrossRefPubMedPubMedCentral
45.
Zheng A, Moritani T. Effect of the combination of ginseng, oriental bezoar and glycyrrhiza on autonomic nervous activity and immune system under mental arithmetic stress. J Nutr Sci Vitaminol (Tokyo). 2008;54(3):244–9.CrossRefPubMed
46.
Mirabi P, Namdari M, Alamolhoda S, Mojab F. The Effect of Melissa Officinalis Extract on the severity of primary Dysmenorrha. Iran J Pharm Res. 2017;16(Suppl):171–7.PubMedPubMedCentral
47.
48.
Park HS, Yun YS, Park JY, Kim YS, Choi JM. Obesity, abdominal obesity, and clustering of cardiovascular risk factors in South Korea. Asia Pac J Clin Nutr. 2003;12(4):411–8.PubMed
49.
Oh JK, Amoranto MBC, Oh NS, Kim S, Lee JY, Oh YN, Shin YK, Yoon Y, Kang DK. Synergistic effect of Lactobacillus gasseri and Cudrania tricuspidata on the modulation of body weight and gut microbiota structure in diet-induced obese mice. Appl Microbiol Biotechnol. 2020;104(14):6273–85.CrossRefPubMed
50.
Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013;34(1):39–58.CrossRefPubMed
51.
Jensen A. Present and future needs for algae and algal products. In: Fourteenth International Seaweed Symposium: 1993: Springer; 1993: 15–23.
Metadata
Title
Anti-obesity effect of Neoagaro-oligosaccharides with overweight and obese subjects: a 16-week, randomized, double-blind, placebo-controlled clinical trial
Authors
Hyang-Im Baek
Ki-Chan Ha
Yu Kyung Park
Je Hyeon Lee
Eun Joo Kim
Hye-Jeong Ko
Jong Cheon Joo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04206-2

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue

Research

Knowledge and experiences of families regarding amber necklaces

Research

Assessment of the phytochemical composition and antimicrobial properties of Tapinanthus bangwensis leaves hosted by the branches of Persea americana

Research

Clinical associations for traditional and complementary medicine use among norwegian cancer survivors in the seventh survey of the Tromsø study: a cross-sectional study

Research

Neuroimaging studies of acupuncture on Alzheimer’s disease: a systematic review

Research

Therapeutic effects of magnesium and vitamin B6 in alleviating the symptoms of restless legs syndrome: a randomized controlled clinical trial

Research

Explore the active ingredients and potential mechanisms of JianPi QingRe HuaYu Methods in the treatment of gastric inflammation-cancer transformation by network pharmacology and experimental validation